Observational studyCancer medicine2026
Risk of 3-Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Tailored cervical cancer screening strategies are essential, particularly in resource-limited settings. This study aimed to assess the genotype-specific impact of high-risk human papillomavirus (HR-HPV) infections on cervical cytological progression over a 3-year interval among Chinese women, thereby providing evidence for more precise and individualized screening approaches. A multicenter cohort was established in 2017 across three Chinese provinces. Participants underwent baseline HPV genotyping and cytological examination, with genotyping for five high-risk types (HPV16, 18, 33, 52, and 58), and follow-up evaluations conducted from 2018 to 2020. Cytological progression was defined as a transition from normal cytology (negative for intraepithelial lesion or malignancy, NILM) at baseline to low-grade squamous intraepithelial lesion (LSIL) or worse at the final follow-up. A total of 7240 women were included to evaluate the cytological progression. The overall progression rate was 0.7%, with a notably higher rate among HR-HPV-positive women (2.1%) compared to HR-HPV-negative women (0.5%). Specifically, HPV16, HPV52, and HPV58 were significantly associated with an increased risk of progression, with adjusted odds ratios (aORs) of 6.26 (95% CI: 2.62-14.95), 6.68 (95% CI: 3.30-13.53), and 4.24 (95% CI: 1.51-11.94), respectively. Moreover, women with persistent infections with HPV16, HPV52, and HPV58 had approximately 8-fold, 6-fold, and 5-fold higher risks of progression, respectively, compared with women without infections. Stratified management based on high-risk genotypes-particularly HPV16, HPV52, and HPV58-may help prioritize colposcopy and more intensive follow-up for women at elevated risk, which could contribute to cervical cancer prevention efforts. Trial Registration: Chinese Clinical Trial Registry Center of the World Health Organization International Clinical Trials Registry Platform number: ChiCRT2200055287.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.